Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Partially aligned: indication and some mechanistic and adverse reaction claims match the provided label, but multiple adverse reaction items are asserted as “common” without support, and the trial description/subpopulation restriction is not supported by the provided label excerpts.
Category Scores
Accurate Statements
RYSTIGGO is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-AChR or anti-MuSK antibody positive.
Supported by 1 INDICATIONS AND USAGE.
Rystiggo is a neonatal Fc receptor (FcRn) antagonist.
Supported by 11 DESCRIPTION and 12 CLINICAL PHARMACOLOGY (12.1) describing binding/blocking FcRn.
By binding FcRn, the drug reduces circulating IgG levels.
Supported by 12 CLINICAL PHARMACOLOGY (12.1).
Headache is among the most common adverse reactions in clinical trials.
Supported by 6.1 Clinical Trial Experience/Table 2 (headache 44% vs 19%).
Diarrhea is among the most common adverse reactions in clinical trials.
Supported by 6.1 Clinical Trial Experience/Table 2 (diarrhea 20% vs 13%).
Nausea is among the most common adverse reactions in clinical trials.
Supported by 6.1 Clinical Trial Experience/Table 2 (nausea 10% vs 8%).
Upper respiratory tract infection is among the adverse reactions listed (including in the common adverse reaction table).
Supported by 6.1 Clinical Trial Experience/Table 2 (upper respiratory tract infection 8% vs 6%).
Joint pain (arthralgia) is among the adverse reactions listed in the common adverse reaction table.
Supported by 6.1 Clinical Trial Experience/Table 2 (arthralgia 7% vs 3%).
Unsupported Statements
In the Phase 3 MYKTAZIA trial, Rystiggo showed statistically significant improvements in MG-ADL score compared to placebo in patients with AChR+ gMG.
Provided label text describes Study 1 (NCT03971422) with statistically significant MG-ADL improvements but does not identify the trial as “MYKTAZIA” or restrict the efficacy results to “AChR+ only” in the provided excerpts.
By blocking FcRn, Rystiggo reduces the levels of disease-associated IgG antibodies, including anti-AChR antibodies.
The provided mechanism section supports reduction of circulating IgG levels, but it does not explicitly support the specific phrase about “including anti-AChR antibodies” within the provided label excerpts.
Common side effects reported in clinical trials include vomiting.
Vomiting is not listed among the most common adverse reactions in the provided adverse reactions summary/table.
Common side effects reported in clinical trials include fatigue.
Fatigue is not listed among the most common adverse reactions in the provided adverse reactions summary/table.
Common side effects reported in clinical trials include muscle spasms.
Muscle spasms are not listed among the most common adverse reactions in the provided adverse reactions summary/table.
Common side effects reported in clinical trials include shortness of breath.
Shortness of breath is not listed among the most common adverse reactions in the provided adverse reactions summary/table.
Common side effects reported in clinical trials include dizziness.
Dizziness is not listed among the most common adverse reactions in the provided adverse reactions summary/table.
Common side effects reported in clinical trials include rash.
Rash is not listed among the most common adverse reactions in the provided adverse reactions summary/table.
Rystiggo is manufactured by UCB.
No provided label excerpt states the manufacturer.
Contradictions
Important Omissions
No dosage and administration details were provided in the AI claims, so the label’s dosing schedule/route specifics cannot be evaluated.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Overstates several adverse reactions as “common” (without support in the provided label) and adds unsupported trial/subgroup specificity; this could misinform expectations about adverse event frequency and efficacy applicability.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple adverse reaction items are labeled as common without support in the provided label excerpts; additionally, the trial name/subgroup restriction and the explicit “anti-AChR antibodies” mechanism are not supported by the provided label text.
Suggested Improvement
Limit adverse reaction claims to those explicitly listed in the provided Table 2/common adverse reaction summary, and remove or rephrase unsupported trial naming/subgroup restriction and mechanism details that do not explicitly mention anti-AChR antibodies in the provided excerpts.